Adaptive radiation planning for anal cancer treatment
Part of Cancer, Digestive system clinical trials.
This trial tests an online, adaptive way to plan and adjust radiation during treatment for people with biopsy-proven anal cancer. The goal is to better target the cancer while keeping side effects as low as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anal cancer confirmed by a tissue biopsy
- Your doctors believe radiation treatment is meant to cure you
- You can read, understand, and sign consent forms (and agree in an oral discussion too)
- You do not have another type of cancer diagnosed or treated within the last 5 years (except basal cell skin cancer)
- You are able to take part in the study procedures for radiation planning and adjustment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an adaptive, image-guided radiation plan for anal canal squamous-type cancers. It may help deliver effective treatment while adjusting the radiation based on how your body and tumor respond.
This trial tests a new, more precise type of radiation therapy for anal cancer. It uses daily MRI scans to adjust the radiation dose based on how the tumor shrinks, aiming to give stronger treatment to the cancer while protecting healthy tissue.
This trial tests a shorter course of radiation therapy given with chemotherapy for people with high-risk anal cancer. The goal is to see if the shorter treatment is just as effective but causes fewer side effects and is more convenient.
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
This trial tests if giving chemotherapy before standard chemoradiation works better than standard chemoradiation alone for people with locally advanced anal cancer that has not spread. It aims to improve treatment outcomes.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Hear when a new Anal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.